Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5887-5892

  Graeser, Monika K ^a   Engel, Christoph ^a   Rhiem, Kerstin ^a   Gadzicki, Dorothea ^a   Bick, Ulrich ^a   Kast, Karin ^a   Froster, Ursula G ^a   Schlehe, Bettina ^a   Bechtold, Astrid ^a   Arnold, Norbert ^a   Preisler Adams, Sabine ^a   Nestle Kraemling, Carolin ^a   Zaino, Mohammad ^a   Loeffler, Markus ^a   Kiechle, Marion ^a   Meindl, Alfons ^a   Varga, Dominic ^a   Schmutzler, Rita K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC COUNSELING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADULT; AGE; BREAST TUMOR; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PEDIGREE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MUTATION; NEOPLASMS, SECOND PRIMARY; PEDIGREE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73349132056     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9430     Document Type: Article

References (17)

1. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
2. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
3. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
4. Pierce LJ, Levin AM, Rebbeck TR, et al: Tenyear multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443, 2006
5. Metcalfe K, Lynch HT, Ghadirian P, et al: Contra-lateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004
6. Metcalfe KA, Lubinski J, Ghadirian P, et al: Predictors of contra-lateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26:1093-1097, 2008
7. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003
8. Antoniou AC, Spurdle AB, Sinilnikova OM, et al: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82:937-948, 2008
9. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Contra-lateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83:384-386, 2000
10. Meindl A: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472-480, 2002
11. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876, 2007
12. Robson M, Svahn T, McCormick B, et al: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. Cancer 103:44-51, 2005
13. Haffty BG, Harrold E, Khan AJ, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471-1477, 2002
14. Seynaeve C, Verhoog LC, van de Bosch LM, et al: Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150-1158, 2004
15. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al: Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21:1675-1681, 2003
16. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al: Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17: 391-400, 2006
17. Tilanus-Linthorst MM, Bartels KC, Alves C, et al: Selection bias influences reported contra-lateral breast cancer incidence and survival in high risk non-BRCA1/2 patients. Breast Cancer Res Treat 95:117-123, 2006